Corbus Pharmaceuticals will host a conference call and webcast on Monday, September 14, 2026, to discuss topline data from its CANYON-1 Phase 1b clinical trial of CRB-913 for obesity. CRB-913 is a peripherally restricted CB1 inverse agonist, offering a potentially new approach to weight management. Dr. Harold Bays, an investigator for the study, will be a guest speaker, providing expert insight into the clinical trial findings and the potential of CRB-913.

L3Harris Technologies (LHX) stock has fallen to a new 52-week low of $246.43, marking a over 31% drop in the past six months despite the company's recent Q2 2026 financial results exceeding Wall Street expectations. InvestingPro analysis suggests the stock is currently undervalued and in oversold territory, potentially indicating a buying opportunity. The downturn reflects broader market trends and company-specific challenges, including uncertainties around a leadership change and the planned IPO of its Missile Solutions segment.

Goldman Sachs has raised its price target for Affirm Holdings (AFRM) to $115, implying a potential 69% upside, due to robust growth in interest-bearing loans, the Affirm Card, and strong Amazon volumes. Other financial firms also share this bullish sentiment, with the average target price around $99.48. Affirm's strong Q4 results, driven by expanding interest-bearing business, rapid Affirm Card adoption, and significant growth opportunities in e-commerce and other sectors, underscore the positive outlook.

SL SPV-2, L.P. and affiliated entities sold approximately $26 million worth of Dell Technologies (NYSE:DELL) Class C Common Stock on September 9, 2026, disposing of 43,198 shares at prices between $534.09 and $550.71. This sale occurred as Dell's stock approached its 52-week high, with InvestingPro indicating it might be overvalued. The company recently reported strong fiscal results and raised its fiscal 2027 guidance, driven by significant AI server demand, leading to positive analyst responses, although some analysts maintain caution on future growth.

Frequency Electronics, Inc. (FEIM) reported record first-quarter fiscal 2027 revenue of $23.5 million, marking a 70% year-over-year increase, and achieved a record funded backlog of $129 million. These strong results have boosted management's confidence in reaching at least $150 million in annual revenue by fiscal 2029. Despite this performance, the company faces challenges including production constraints, limited success in new defense technology markets, and high short interest.

Frequency Electronics (FEIM) reported record revenue of $23.5 million for Q1 fiscal 2027, up 70% year-over-year, and a funded backlog of $129 million. This strong performance has increased confidence in reaching $150 million in annual revenue by fiscal 2029 and led to significant improvements in profitability. Despite challenges like production ramp-up and limited defense market success, hedge fund interest in the stock has risen, although short interest remains high.

Jim Cramer highlighted Oracle's massive $664 billion revenue backlog, a significant increase from previous years, as a sign of dramatic growth opportunity. However, despite this positive outlook, the article points out underlying concerns such as substantial capital expenditures, negative free cash flow, and founder Larry Ellison's plan to sell $7.5 billion in stock. The company's stock is also significantly down year-over-year, prompting questions about how much of the backlog will convert to recognized revenue amidst funding challenges.

This article provides a business profile of Fortis Inc. (TSX:FTS), highlighting its operations in regulated electric and gas utility networks across Canada, the United States, and the Caribbean. It discusses how Fortis's performance is tied to service delivery, asset availability, and customer demand, within the context of the S&P/TSX 60 index. The company is also noted for its connection to the Dividend Stocks category.

Short interest in First Trust Emerging Markets AlphaDEX Fund (FEM) surged by 262.1% in August, reaching 137,270 shares, which represents about 0.6% of its outstanding shares and a short-interest ratio of 1.9 days. The fund's shares recently traded at $33.44, near its 12-month high, and it increased its quarterly dividend to $0.1899 per share, resulting in a 2.3% yield. Several institutional investors, including Morgan Stanley and LPL Financial LLC, significantly expanded their holdings in FEM during recent quarters.

Kimberly-Clark (KMB) recently extended its 54-year dividend increase streak while simultaneously pursuing a $48.7 billion acquisition of Kenvue (KVUE), raising concerns among income investors. The company's operating cash flow barely covers its current dividend and capital expenditure, and the Kenvue deal is expected to put significant pressure on its balance sheet. While management expresses confidence in synergies from the acquisition, the market is pricing in real risk, as KMB shares have fallen 20% over the past year, pushing its dividend yield to 5%.